Skip to main content


The honest response is to stop designing trials around inert placebos and build more credible control conditions. That means active comparators like low-dose stimulants, niacin, or sub-therapeutic microdoses, combined with centralized raters who are blinded to the patient's dosing experience and kept structurally separate from the therapeutic team. https://salienceclinical.com/